跳至主要内容
临床试验/NCT06609746
NCT06609746尚未招募不适用

The Effect of Low FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides and Polyols) Diet with Thyme on Clinical Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 52 人开始时间: 2024年10月21日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
52
主要终点
Irritable Bowel Syndrome symptom severity score

研究概览

简要总结

The goal of this clinical trial is to learn if thyme supplement enhances the effects of a low FODAMP diet on reducing clinical symptoms and improving the quality of life of patients with irritable bowel syndrome or not.

The main questions it aims to answer are:

  1. Does consumption of thyme reduce the severity score of clinical symptoms in patients with irritable bowel syndrome?
  2. Does consumption of thyme increase the quality of life score in patients with irritable bowel syndrome? Researchers will compare thyme supplementation with placebo to see if thyme supplement enhances the effects of a low FODAMP diet on clinical symptoms and quality of life in patients with irritable bowel syndrome.

Participants will:

  1. Receive thyme supplement plus a low FODMAP diet or placebo with low FODMAP diet for 8 weeks.
  2. Recorde 3 days (1weekend and 2 workday) dietary recalls at week 4 and week 8 to assess adherence to the low FODMP diet.
  3. Visit the clinic at the beginning of the study and the end of the study for a check-up and score record

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 18-65;
  • Patients with irritable bowel syndrome;
  • Body Mass Index in the range of 18-25 kg/m2

排除标准

  • Any organic intestinal disease;
  • Medical history of chronic gastrointestinal and colorectal disease;
  • Any major bowel surgery;
  • Medical history of liver and kidney disorders;
  • Regular use of laxative, anti-diarrhea and anti inflammatory medications.

结局指标

主要结局

Irritable Bowel Syndrome symptom severity score

时间窗: baseline and 8 weeks following therapy

The primary outcome measure will be a change in the Irritable Bowel Symptom Severity Scale (IBS-SS) from baseline to 8 weeks at the conclusion of therapy. The IBS-SS scale ranges from 0 to 500 . Scores of 75-175, 175-300, and 300-500 indicate mild, moderate, and severe cases.

次要结局

  • Defecation frequency(baseline and 8 weeks following therapy)
  • Stool consistency(baseline and 8 weeks following therapy)
  • Quality of life score(baseline and 8 weeks following therapy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Samira Rastgoo

Principal Investigator

Shahid Beheshti University of Medical Sciences

相似试验